GlobeNewswire Inc.··Not SpecifiedNxera Pharma Hits Second Eli Lilly Milestone in Metabolic Disease Push
Nxera Pharma achieves second milestone with Eli Lilly validating its GPCR-targeting platform. Deal includes $694M in potential payments plus royalties.
LLYdiabetesdrug discovery